Technical Analysis for GLYC - GlycoMimetics, Inc.

Grade Last Price % Change Price Change
grade C 14.15 -0.70% -0.10
GLYC closed down 0.7 percent on Friday, October 19, 2018, on approximately normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical GLYC trend table...

Date Alert Name Type % Chg
Oct 19 50 DMA Resistance Bearish 0.00%
Oct 19 Shooting Star Candlestick Bearish 0.00%
Oct 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Oct 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.70%
Oct 18 Crossed Above 20 DMA Bullish -0.70%
Oct 18 Outside Day Range Expansion -0.70%
Oct 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.36%
Oct 17 MACD Bullish Signal Line Cross Bullish 1.36%
Oct 17 NR7 Range Contraction 1.36%
Oct 17 Inside Day Range Contraction 1.36%

Older signals for GLYC ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Is GLYC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.05
52 Week Low 10.41
Average Volume 275,172
200-Day Moving Average 17.3896
50-Day Moving Average 14.4566
20-Day Moving Average 14.016
10-Day Moving Average 13.688
Average True Range 0.6001
ADX 24.64
+DI 16.9007
-DI 17.0447
Chandelier Exit (Long, 3 ATRs ) 13.0097
Chandelier Exit (Short, 3 ATRs ) 14.7603
Upper Bollinger Band 14.9153
Lower Bollinger Band 13.1167
Percent B (%b) 0.57
BandWidth 12.832477
MACD Line -0.1608
MACD Signal Line -0.2351
MACD Histogram 0.0743
Fundamentals Value
Market Cap 463.03 Million
Num Shares 32.7 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -10.56
Price-to-Sales 18873.21
Price-to-Book 3.02
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.13
Resistance 3 (R3) 15.20 14.94 14.96
Resistance 2 (R2) 14.94 14.70 14.91 14.91
Resistance 1 (R1) 14.55 14.54 14.42 14.48 14.85
Pivot Point 14.29 14.29 14.23 14.26 14.29
Support 1 (S1) 13.90 14.05 13.77 13.83 13.45
Support 2 (S2) 13.64 13.89 13.61 13.39
Support 3 (S3) 13.25 13.64 13.34
Support 4 (S4) 13.18